Related Experiment Video
Updated: Jun 6, 2026
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Comparative efficacy of therapeutic modalities for metastatic uveal melanoma: a systemic review and network
Qinyun Chen1, Jie Zhou2, Hongli Zhou2
1Department of Ophthalmology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
Objective:
To evaluate the efficacy of different therapeutic modalities in the treatment of metastatic uveal melanoma (mUM).
Methods:
According to PRISMA criteria, We identified relevant randomized controlled trials (RCTs) by searching PubMed, Embase, and The Cochrane Library through March 31, 2026. Patients with liver metastatic uveal melanoma were enrolled. The analysis of clinical prognostic factors was performed using R 4.2.0. The main outcomes measured were overall survival (OS) and progression-free survival (PFS).
Results:
A total of 16 articles were screened between 2000 and 2026, involving 2585 patients. The trials evaluated eight treatment approaches: tebentafusp, immune checkpoint inhibitors (ICIs), targeted therapy, targeted therapy plus chemotherapy, chemotherapy, liver-directed therapy (LDT), liver-directed therapy combined with ICIs, and liver-directed therapy plus chemotherapy. The results of the included trials showed that in terms of overall survival and progression-free survival, the liver-directed therapy combined with ICIs were the most effective regardless of the HLA genotype. Tebentafusp showed the second-best OS but the worst PFS among the compared treatments. Immune checkpoint inhibitors were inferior to tebentafusp in improving OS but were superior in PFS. Furthermore, compared with conventional systemic chemotherapy, targeted therapy, or their combination, regional liver-directed therapy demonstrated more favorable outcomes in both OS and PFS. Emerging immunotherapies (e.g., tumor vaccines, oncolytic virotherapy, tumor-infiltrating lymphocytes) and novel targeted agents could not be included in the NMA due to the absence of comparative trials or ongoing investigations.
Conclusion:
The liver-directed therapy combined with ICIs achieved the best results compared to Tebentafusp, ICIs and other therapeutic modality for OS and PFS extension in metastatic uveal melanoma based on available data. Future comparative studies incorporating emerging therapies are warranted.
Systematic Review Registration:
https://www.crd.york.ac.uk/prospero/, identifier CRD420261393862.
Insights
Liver-directed therapy combined with immune checkpoint inhibitors (ICIs) offers the best survival outcomes for metastatic uveal melanoma. This combination therapy shows superior overall survival and progression-free survival compared to other treatments.
Area of Science:
- Oncology
- Medical Research
- Clinical Trials
Background:
- Metastatic uveal melanoma (mUM) is a rare and aggressive cancer with limited treatment options.
- Evaluating the efficacy of various therapeutic modalities is crucial for improving patient outcomes.
Purpose of the Study:
- To compare the effectiveness of different treatments for metastatic uveal melanoma.
- To identify the optimal therapeutic strategy for improving overall survival (OS) and progression-free survival (PFS).
Main Methods:
- A systematic review and meta-analysis of randomized controlled trials (RCTs) were conducted following PRISMA criteria.
- Searches were performed on PubMed, Embase, and The Cochrane Library up to March 31, 2026.
- Included studies focused on patients with liver metastatic uveal melanoma, analyzing OS and PFS.
Main Results:
- Sixteen articles involving 2585 patients evaluated eight treatment approaches.
- Liver-directed therapy combined with immune checkpoint inhibitors (ICIs) demonstrated the most significant improvements in OS and PFS.
- Tebentafusp showed the second-best OS but the worst PFS; ICIs were superior to tebentafusp in PFS but inferior in OS.
Conclusions:
- Liver-directed therapy combined with ICIs is the most effective treatment for metastatic uveal melanoma based on current data.
- This combination therapy significantly enhances OS and PFS compared to tebentafusp, ICIs, and other modalities.
- Further comparative studies are needed to evaluate emerging immunotherapies and targeted agents.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...